DENTSPLY SIRONA (NASDAQ:XRAY) Downgraded by Jefferies Financial Group to “Hold”

Jefferies Financial Group cut shares of DENTSPLY SIRONA (NASDAQ:XRAY) from a buy rating to a hold rating in a research report released on Thursday morning, MarketBeat reports. The brokerage currently has $20.00 price objective on the medical instruments supplier’s stock, down from their previous price objective of $30.00.

XRAY has been the subject of several other research reports. Needham & Company LLC dropped their price target on shares of DENTSPLY SIRONA from $34.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Leerink Partners downgraded DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Barrington Research cut their price target on shares of DENTSPLY SIRONA from $36.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. UBS Group decreased their price objective on shares of DENTSPLY SIRONA from $35.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, December 3rd. Finally, Robert W. Baird cut their target price on shares of DENTSPLY SIRONA from $31.00 to $24.00 and set a “neutral” rating on the stock in a research note on Friday, November 8th. Ten investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $26.67.

DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $19.44 on Thursday. DENTSPLY SIRONA has a fifty-two week low of $17.21 and a fifty-two week high of $35.68. The stock has a fifty day moving average of $18.98 and a two-hundred day moving average of $22.74. The company has a current ratio of 1.25, a quick ratio of 0.84 and a debt-to-equity ratio of 0.72.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.50 EPS for the quarter, beating the consensus estimate of $0.48 by $0.02. The firm had revenue of $951.00 million during the quarter, compared to analyst estimates of $939.10 million. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.49 earnings per share. Equities research analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 10th. Investors of record on Friday, December 27th were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 3.29%. The ex-dividend date of this dividend was Friday, December 27th. DENTSPLY SIRONA’s dividend payout ratio is currently -30.92%.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of hedge funds have recently bought and sold shares of XRAY. Pacer Advisors Inc. boosted its stake in shares of DENTSPLY SIRONA by 15,105.1% during the 4th quarter. Pacer Advisors Inc. now owns 4,503,591 shares of the medical instruments supplier’s stock valued at $85,478,000 after buying an additional 4,473,972 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in DENTSPLY SIRONA by 206.3% in the third quarter. JPMorgan Chase & Co. now owns 1,847,389 shares of the medical instruments supplier’s stock valued at $49,990,000 after acquiring an additional 1,244,326 shares in the last quarter. Invenomic Capital Management LP bought a new position in DENTSPLY SIRONA during the 3rd quarter valued at $23,724,000. National Bank of Canada FI grew its holdings in DENTSPLY SIRONA by 85.8% during the 3rd quarter. National Bank of Canada FI now owns 1,628,200 shares of the medical instruments supplier’s stock worth $44,059,000 after acquiring an additional 751,800 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of DENTSPLY SIRONA by 50.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,065,773 shares of the medical instruments supplier’s stock worth $55,900,000 after purchasing an additional 692,100 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.